STOCK TITAN

Viking Therapeutics, Inc. (VKTX) awards director new options and RSUs

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Dorothy Elizabeth Kelly-Gemmell, a director of Viking Therapeutics, Inc., received equity awards on August 1, 2026. She was granted a restricted stock unit award covering 6,333 shares of common stock, vesting in three equal annual installments, and stock options for 40,800 shares at an exercise price of $31.74 per share, also vesting one-third on each anniversary and expiring on August 1, 2036.

Positive

  • None.

Negative

  • None.
Insider Kelly-Gemmell Dorothy Elizabeth
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) F2 40,800 $0.00 $0.00
Grant/Award Common Stock, par value $0.00001 per share F1 6,333 $0.00 $0.00
Holdings After Transaction: Stock Option (Right to Buy) — 40,800 shares (Direct); Common Stock, par value $0.00001 per share — 6,333 shares (Direct)
Footnotes (2)
  1. F1. Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award.
  2. F2. One-third of the shares subject to the option will vest on each anniversary of the grant date.
RSU shares granted 6,333 shares Restricted stock units of common stock granted on 2026-08-01
Option shares granted 40,800 shares Stock options granted on 2026-08-01
Option exercise price $31.74 per share Exercise price for 40,800 stock options
Option expiration date 2036-08-01 Expiration date of the reported stock options
RSU vesting schedule One-third per year One-third of RSU shares vest on each one-year anniversary
Option vesting schedule One-third per year One-third of option shares vest on each anniversary of grant date
restricted stock unit financial
"Represents a restricted stock unit award RSU of common stock"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Equity Incentive Plan financial
"under the Issuer's 2024 Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What equity awards did Viking Therapeutics (VKTX) director Dorothy Elizabeth Kelly-Gemmell receive on August 1, 2026?

Dorothy Elizabeth Kelly-Gemmell received 6,333 RSUs and stock options for 40,800 shares of Viking Therapeutics common stock. Both awards vest in three equal annual installments starting on the first anniversary of the grant date.

How many RSUs did Viking Therapeutics (VKTX) grant and how do they vest?

Viking Therapeutics granted 6,333 restricted stock units of common stock to director Dorothy Elizabeth Kelly-Gemmell. According to the award terms, one-third of the RSU shares vests on each one-year anniversary of the August 1, 2026 grant date, over three years.

What are the key terms of the VKTX stock options granted to Dorothy Elizabeth Kelly-Gemmell?

She received stock options for 40,800 shares of Viking Therapeutics common stock with an exercise price of $31.74 per share. One-third vests on each anniversary of the August 1, 2026 grant date, and the options expire on August 1, 2036.

When do the Viking Therapeutics (VKTX) RSUs and options begin to vest for Dorothy Elizabeth Kelly-Gemmell?

Both the 6,333 RSUs and the 40,800 stock options begin vesting on the first anniversary of the August 1, 2026 grant date. One-third of the shares under each award vests on each subsequent one-year anniversary.

Are Dorothy Elizabeth Kelly-Gemmell’s VKTX equity awards reported as part of a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirmed, and the footnotes describe only vesting terms. The disclosure does not state that these particular RSU and option grants were made under a Rule 10b5-1 trading plan.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kelly-Gemmell Dorothy Elizabeth

(Last)(First)(Middle)
9920 PACIFIC HEIGHTS BLVD
SUITE 500

(Street)
SAN DIEGO CALIFORNIA 92121

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Viking Therapeutics, Inc. [ VKTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock, par value $0.00001 per share08/01/2026A6,333(1)A$06,333D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$31.7408/01/2026A40,80008/01/2027(2)08/01/2036Common Stock40,800$040,800D
Explanation of Responses:
1. Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award.
2. One-third of the shares subject to the option will vest on each anniversary of the grant date.
/s/ Michael Morneau, as Attorney-in-Fact08/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)